In the bustling world of healthcare and medicine, keeping abreast of medication safety is paramount. Amidst the multitude of drugs that hit the market, the recent spotlight is on several noteworthy names: Semaglutide, Saxenda, Wegovy, Trulicity, Victoza, Soliqua, Rybelsus, Ozempic, and Mounjaro. Let’s embark on a journey to understand the concerns arising from these names, as addressed by HSA Singapore.

The Modern Age of Weight Management

The 21st century brought about several innovations in healthcare, with weight management solutions standing out prominently. Among them, Semaglutide, Saxenda, Wegovy, Trulicity, and others have grabbed the spotlight.

But how do they fit into Singapore’s health landscape? Let’s delve deeper.

A Glimpse into GLP-1 RAs

The world of medicine is abuzz with terms. One such class is GLP-1 RAs.

GLP-1 receptor agonists (GLP-1 RAs) are remarkable pharmaceuticals that address crucial aspects of health. They regulate appetite, enhance insulin secretion, and control calorie intake, making them valuable tools in both weight management and the treatment of Type 2 Diabetes Mellitus.

These medications offer hope for individuals striving to achieve a healthier and more balanced lifestyle.

The GLP-1 RA Medications Under the Spotlight

Semaglutide, Saxenda, and Wegovy: A Closer Look

The story begins with Saxenda (Liraglutide) and Wegovy (Semaglutide), two medications authorised for weight management in the European Union. Ozempic (Semaglutide) also came in to the spotlight as it has been widely used off-label for weight loss. These GLP-1 RAs are designed to regulate appetite, control calorie intake, and aid in weight loss. However, recent reports raised concerns about their potential association with suicidal thoughts and self-harm.

The Icelandic medicines agency flagged these issues, prompting regulatory authorities to investigate further.

International Investigations: EMA and UK MHRA Join In

The concern about these GLP-1 RAs didn’t stay confined to Singapore. The European Medicines Agency (EMA) and the UK Medicines and Healthcare Products Regulatory Agency (UK MHRA) took notice and initiated their reviews. The EMA started by scrutinising the reports related to Saxenda, and Wegovy in July 2023.

While these medications are authorized for weight management in the EU, they sought to ascertain whether the reported suicidal thoughts and self-harm cases had a direct link to these drugs, underlying patient conditions, or other factors.

As the investigation progressed, the EMA extended its review to encompass the entire class of GLP-1 RAs, reflecting the seriousness of the situation. The UK MHRA followed suit by launching its review, driven by domestic reports of suicidal and self-injurious behavior associated with Liraglutide and Semaglutide.

Local Perspective: HSA Singapore’s Vigilance

In Singapore, there are currently eight GLP-1 RA products registered. These include Saxenda (Liraglutide), Wegovy (Semaglutide), Trulicity (Dulaglutide), Victoza (Liraglutide), Soliqua (Lixisenatide with insulin glargine), Rybelsus (Semaglutide), Ozempic (Semaglutide) and Mounjaro (Tirzepatide).

At present, HSA Singapore has not received any local adverse event reports of suicidal thoughts or self-harm linked to GLP-1 RAs. Nevertheless, HSA remains vigilant and continues to closely monitor international developments regarding the safety of these medications. Their collaboration with local product registrants underscores their commitment to ensuring patient safety.

HSA’s Advisory: A Call for Reporting

In light of these ongoing investigations, HSA Singapore has issued an advisory to healthcare professionals. They advise exercising caution when using GLP-1 RAs and stress the importance of reporting any suspected serious adverse events.

Reporting can be done through various channels, including the Adverse Drug Reactions/Drug Allergy module of the Critical Medical Information Store (CMIS), online reporting on the HSA website, or through a mobile-friendly E-form.

Your Health, Your Decision

It’s important to remember that using GLP-1 receptor agonists is still a medical decision. There are specific guidelines, such as a BMI of 27 or more, and realistic expectations, typically involving a 5-15% weight loss target over a period of 16 weeks or more. At Sire, we work closely with you to evaluate your suitability for these medications, ensuring that your health remains our top priority.

Why Choose Sire’s Weight Management Solutions?

Sire isn’t just another health clinic; it’s a comprehensive digital platform designed exclusively for men. Here’s why Singaporean men should consider Sire

Doctor-Led Consultations: Every weight loss journey at Sire starts with a consultation from experienced doctors. We ensure the methods employed are safe and tailored for the individual by integrating doctor consultations with every treatment plan, offering men the assurance of quality and safety with authorized products in their arsenal.

Authorised Products: Sire doesn’t compromise on quality. All products prescribed are registered with the HSA and approved by the Ministry of Health, ensuring men get the best in class treatment without any concerns about authenticity or effectiveness.

Safety First: With Sire, men are in safe hands. The weight management solutions are not just effective but also ensure users lose up to 20% of their weight safely under the guidance of professionals.

Discretion Guaranteed: In a society where weight issues can sometimes be stigmatised, Sire promises discretion. This makes it easier for men to approach, discuss, and find solutions to their weight concerns without any apprehension.

Health and Safety: A Priority at Sire

In the fast-paced world of Singapore, health often takes a backseat. However, with increasing awareness, men are actively seeking solutions to their health concerns. Sire, understanding this trend, places paramount importance on health and safety.

Their approach is not about quick fixes but sustainable solutions. By integrating doctor consultations with every treatment plan, they ensure that the methods employed are safe and tailored for the individual. With authorised products in their arsenal, men can be assured of the quality and safety of the treatments they’re receiving.

In conclusion, for Singaporean men looking for a holistic, safe, and effective weight management solution, Sire stands out as the go-to digital health clinic.

Summary

In the battle against obesity, medications like Semaglutide, Saxenda, and Wegovy have brought hope. But safety concerns, including links to suicidal thoughts and self-harm, have triggered global regulatory reviews.

HSA Singapore, in collaboration with international partners, prioritises patient safety. They urge healthcare professionals to monitor and report adverse events.

For effective weight management, GLP-1 receptor agonists like Semaglutide, Saxenda, Wegovy, and others hold promise. But these decisions are medical, guided by guidelines. At Sire’, we’re here to help you navigate this journey, assess your suitability, and make informed choices for a healthier life. Contact us today to start this transformative journey together.

Frequently Asked Questions (FAQs)

Q: What are GLP-1 RAs, and what are their uses?

Doctors prescribe GLP-1 RAs as medications to regulate appetite and calorie intake for weight management and/or to treat Type 2 diabetes mellitus (T2DM).

Q: Are these medications still available for use during the review?

Yes, these medications still remain available for use. Healthcare professionals are advised by the HSA to exercise caution and monitoring when prescribing these medications. Healthcare professionals are advised to report suspected serious adverse events such as suicidal thoughts or self-harm to the HSA.

Q: Are Semaglutide, Saxenda, and Wegovy the only medications under review?

Initially, Saxenda and Wegovy were under review, but the investigation was expanded to include the entire class of GLP-1 RAs due to emerging concerns.

Q: Has HSA Singapore received any local adverse event reports regarding GLP-1 RAs?

At present, HSA Singapore has not received any local adverse event reports of suicidal thoughts or self-harm associated with GLP-1 RAs.

Q: Are the weight loss products prescribed by Sire safe and authorised?

Yes. All weight loss products prescribed by Sire are registered with the Health Sciences Authority in Singapore and approved by the Ministry of Health (MOH). We can be assured of their safety and efficacy.

Q: How does Sire’s weight management program work?

Sire’s weight management program starts with a doctor-led consultation to create a personalised plan. It may include authorised medications, dietary recommendations, and exercise guidance.